Christopher D. Byrne

48.0k total citations · 23 hit papers
502 papers, 27.0k citations indexed

About

Christopher D. Byrne is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Christopher D. Byrne has authored 502 papers receiving a total of 27.0k indexed citations (citations by other indexed papers that have themselves been cited), including 312 papers in Epidemiology, 207 papers in Endocrinology, Diabetes and Metabolism and 112 papers in Hepatology. Recurrent topics in Christopher D. Byrne's work include Liver Disease Diagnosis and Treatment (292 papers), Diet, Metabolism, and Disease (131 papers) and Liver Disease and Transplantation (78 papers). Christopher D. Byrne is often cited by papers focused on Liver Disease Diagnosis and Treatment (292 papers), Diet, Metabolism, and Disease (131 papers) and Liver Disease and Transplantation (78 papers). Christopher D. Byrne collaborates with scholars based in United Kingdom, Italy and China. Christopher D. Byrne's co-authors include Giovanni Targher, Alessandro Mantovani, Herbert Tilg, Eleonora Scorletti, Sarah H. Wild, Amedeo Lonardo, Giacomo Zoppini, Ming‐Hua Zheng, Kathleen E. Corey and Ki‐Chul Sung and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Christopher D. Byrne

490 papers receiving 26.5k citations

Hit Papers

NAFLD: A multisystem disease 2012 2026 2016 2021 2015 2016 2021 2020 2018 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. NAFLD: A multisystem disease
    2015 2.3k citations Christopher D. Byrne, Giovanni Targher profile →
  2. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
    2016 1.0k citations Giovanni Targher, Christopher D. Byrne et al. profile →
  3. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
    2021 553 citations Giovanni Targher, Christopher D. Byrne et al. profile →
  4. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
    2020 539 citations Giovanni Targher, Christopher D. Byrne et al. profile →
  5. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
    2018 449 citations Alessandro Mantovani, Christopher D. Byrne et al. Diabetes Care profile →
  6. Complications, morbidity and mortality of nonalcoholic fatty liver disease
    2020 405 citations Alessandro Mantovani, Eleonora Scorletti et al. Metabolism profile →
  7. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
    2021 379 citations Alessandro Mantovani, Christopher D. Byrne et al. profile →
  8. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
    2012 366 citations Philip C. Calder, Christopher D. Byrne et al. profile →
  9. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
    2015 353 citations Christopher D. Byrne, Giovanni Targher et al. profile →
  10. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
    2024 349 citations Giovanni Targher, Christopher D. Byrne et al. profile →
  11. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
    2021 346 citations Giovanni Targher, Christopher D. Byrne et al. profile →
  12. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
    2020 321 citations Alessandro Mantovani, Christopher D. Byrne et al. profile →
  13. NAFLD as a driver of chronic kidney disease
    2020 317 citations Christopher D. Byrne, Giovanni Targher profile →
  14. Current status and future trends of the global burden of MASLD
    2024 299 citations Giovanni Targher, Christopher D. Byrne et al. profile →
  15. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
    2017 293 citations Giovanni Targher, Christopher D. Byrne et al. profile →
  16. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
    2020 255 citations Alessandro Mantovani, Christopher D. Byrne et al. profile →
  17. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
    2021 236 citations Alessandro Mantovani, Christopher D. Byrne et al. profile →
  18. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
    2020 228 citations Christopher D. Byrne et al. profile →
  19. MAFLD and risk of CKD
    2020 209 citations Dan‐Qin Sun, Giovanni Targher et al. Metabolism profile →
  20. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease
    2022 160 citations Christopher D. Byrne et al. profile →
  21. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
    2023 77 citations Giovanni Targher, Alessandro Mantovani et al. profile →
  22. Steatotic liver disease, MASLD and risk of chronic kidney disease
    2023 73 citations Josh Bilson, Alessandro Mantovani et al. profile →
  23. Metabolic Dysfunction–Associated Steatotic Liver Disease
    2025 19 citations Giovanni Targher, Christopher D. Byrne et al. profile →

Peers

Christopher D. Byrne
Comparison fields: 5 of 182
  • Epidemiology 17.1k
  • Endocrinology, Diabetes and Metabolism 10.5k
  • Hepatology 5.2k
  • Physiology 4.7k
  • Cardiology and Cardiovascular Medicine 4.2k
Replace Giulio Marchesini with:
Giulio Marchesini Italy
Jeanne M. Clark United States
Giovanni Targher Italy
Elisabetta Bugianesi Italy
Enzo Bonora Italy
Leon A. Adams Australia
Arthur J. McCullough United States
Hannele Yki‐Järvinen Finland
Linda Henry United States
Mark L. Van Natta United States
Giulio Marchesini Italy View profile →
Citations per field, relative to Christopher D. Byrne
Christopher D. Byrne · 1×
Citations per year, relative to Christopher D. Byrne
Christopher D. Byrne · 1×

Countries citing papers authored by Christopher D. Byrne

Since Specialization
Citations

This map shows the geographic impact of Christopher D. Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher D. Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher D. Byrne more than expected).

Fields of papers citing papers by Christopher D. Byrne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher D. Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher D. Byrne. The network helps show where Christopher D. Byrne may publish in the future.

Co-authorship network of co-authors of Christopher D. Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher D. Byrne. A scholar is included among the top collaborators of Christopher D. Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher D. Byrne. Christopher D. Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Oxidized-LDL aggravates renal injury via tubular cuproptosis
2025 ·Cellular Signalling ·Dan‐Qin Sun, (unknown), Jiahui Zhang, Hong Tang, Bin Hu, Jiaqi Shen, Yan Feng, Xinyu Xu, Ke Chen, Giovanni Targher, Christopher D. Byrne, (unknown), Jing Zhao, Ruifang Wang
2
2
Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
2024 ·Diabetes Obesity and Metabolism ·Xiaodong Zhou, (unknown), Qin‐Fen Chen, Michael D. Shapiro, Gregory Y.H. Lip, Lili Chen, Giovanni Targher, Christopher D. Byrne, (unknown), (unknown), (unknown), Yan Ni, Ming‐Hua Zheng
8
3
MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis
2024 ·Liver International ·Alessandro Mantovani, (unknown), (unknown), (unknown), (unknown), Stefano Bonapace, Salvatore Petta, Stergios A. Pοlyzos, Christopher D. Byrne, Giovanni Targher
10
4
Serum dithiothreitol-oxidizing capacity (DOC) is a promising biomarker for excluding significant liver fibrosis: a proof-of-concept study
2024 ·BMC Medicine ·(unknown), Yafei Zhang, (unknown), Ke Zhang, Bingyan Liu, Peixin Zhang, Qianqian Tang, (unknown), (unknown), (unknown), Ni Zhang, Giovanni Targher, Christopher D. Byrne, Zhenhua Zhang, Ming‐Hua Zheng, Jinsong Zhang
3
5
Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities
2024 ·PubMed ·Gong Feng, (unknown), (unknown), Giovanni Targher, Christopher D. Byrne, Ming‐Hua Zheng
2
6
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
2023 ·JAMA Network Open ·Sungho Bea, Han Eol Jeong, Kristian B. Filion, (unknown), Young Min Cho, (unknown), Yoosoo Chang, Christopher D. Byrne, Ju‐Young Shin
9
7
Balanced crystalloids (RInger’s lactate) versus normal Saline in adults with diabetic Ketoacidosis in the Emergency Department (BRISK-ED): a pilot randomised controlled trial
2023 ·Emergency Medicine Journal ·Justin W. Yan, (unknown), Kristine Van Aarsen, Yun‐Hee Choi, Christopher D. Byrne, Naveen Poonai, (unknown), Kristin K. Clemens
4
8
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study
2023 ·Hepatology Research ·(unknown), Won Sohn, Yoosoo Chang, Yoosun Cho, Min‐Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
1
9
Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD
2023 ·Metabolism ·Josh Bilson, (unknown), (unknown), Eleonora Scorletti, Paul R. Afolabi, Jenny Lord, Laure B. Bindels, Giovanni Targher, Sumeet Mahajan, Diana Baralle, Philip C. Calder, Christopher D. Byrne, Jaswinder K. Sethi
9
10
Serum 25-Hydroxyvitamin D Levels and Risk of Colorectal Cancer: An Age-Stratified Analysis
2023 ·Gastroenterology ·Yejin Kim, Yoosoo Chang, Yoosun Cho, (unknown), Kyungeun Kim, Dong Il Park, Soo‐Kyung Park, Hee‐Kyung Joh, Mi Kyung Kim, Chanmin Kim, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
13
11
Clinical science: Type 2 diabetes
2020 ·Diabetic Medicine ·(unknown), Christopher D. Byrne, Zaed Hamady, Alison K. Wright, Matthew Carr, Tianyi Huang, Hassan S. Dashti, Sushant Saluja, Susan Redline, Simon Anderson, Martin K. Rutter, (unknown), Sviatlana Zhyzhneuskaya, Carl Peters, Alison C. Barnes, Kieren G. Hollingsworth, Naveed Sattar, MEJ Lean, Roy Taylor, (unknown)
0
12
Factors independently associated with cardiorespiratory fitness in patients with non‐alcoholic fatty liver disease
2020 ·Liver International ·Paul R. Afolabi, Eleonora Scorletti, Philip C. Calder, Christopher D. Byrne
6
13
Integrated Professional Component Plan From Freshman Experience To Senior Project
2020 ·(unknown), Christopher D. Byrne, (unknown), (unknown)
0
14
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
2018 ·Molecular Aspects of Medicine ·Eleonora Scorletti, Christopher D. Byrne
125
15
Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis
2016 ·Digestive Diseases ·Eleonora Scorletti, Christopher D. Byrne
33
16
Dorothy Hodgkin Lecture 2012* Non‐alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management
2012 ·Diabetic Medicine ·Christopher D. Byrne
79
17
Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes
2012 ·Diabetes Care ·Ki‐Chul Sung, (unknown), Sarah H. Wild, Christopher D. Byrne
179
18
The metabolic syndrome: science and clinical practice
2011 ·Wiley-Blackwell eBooks ·Christopher D. Byrne, Sarah H. Wild
1
19
The metabolic syndrome
2005 ·Wiley eBooks ·Christopher D. Byrne, Sarah H. Wild
19
20
Prevention of type 2 diabetes and associated cardiovascular disease
2001 ·ePrints Soton (University of Southampton) ·Sarah H. Wild, Christopher D. Byrne
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giulio Marchesini Breakdown of academic impact, for papers by Jeanne M. Clark Breakdown of academic impact, for papers by Giovanni Targher Breakdown of academic impact, for papers by Elisabetta Bugianesi Breakdown of academic impact, for papers by Enzo Bonora Breakdown of academic impact, for papers by Leon A. Adams Breakdown of academic impact, for papers by Arthur J. McCullough Breakdown of academic impact, for papers by Hannele Yki‐Järvinen Breakdown of academic impact, for papers by Linda Henry Breakdown of academic impact, for papers by Mark L. Van Natta
Rankless by CCL
2026